Tag Archive for: drug discovery

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress

Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is reported: CD43s, a sialylated-glyco epitope, and U5snRNP200, an ectopically expressed antigen highly specific for AML blast. Lead program KBA1412 is advancing […]

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

Experienced, innovative biotech and pharma leader with demonstrated success in discovery and development of new therapeutic technologies  Amsterdam, NLD – 5 December 2023 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as […]

Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s Disease

International research collaboration between Harvard Medical School, Cambridge University and Mission Therapeutics CAMBRIDGE, UK, 13 November, 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s Disease (PD) mouse model’ in the journal Nature […]

Curve Therapeutics Expands Leadership Team and Scientific Advisory Board

Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets Prof. Julian Downward (Francis Crick Institute) and Prof. Steven Benkovic (Penn State University) join the Scientific Advisory Board Relocation to bespoke laboratories and offices at Southampton Science Park Read more…

STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme

03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK to research and develop new drugs directed against a unique SARS-CoV2 protein utilizing STORM’s proprietary RNA epigenetic platform. Read more…